NCT06918431 - Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 26, 2025

Primary Completion Date

April 15, 2028

Study Completion Date

April 15, 2028

Conditions

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeLymphoblastic Lymphoma

Interventions

DRUG

Asparaginase Erwinia chrysanthemi

Given IM

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration and/or biopsy

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow aspiration and/or biopsy

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

DRUG

Cyclophosphamide

Given IV

DRUG

Cytarabine

Given IT

DRUG

Cytarabine

Given IV or SC

DRUG

Daunorubicin Hydrochloride

Given IV

DRUG

Dexamethasone

Given PO

PROCEDURE

Echocardiography

Undergo echocardiography

PROCEDURE

Lumbar Puncture

Undergo lumbar puncture

DRUG

Mercaptopurine

Given PO

DRUG

Methotrexate

Given IT

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

BIOLOGICAL

Rituximab

Given IV

DRUG

Vincristine Sulfate

Given IV

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

44195

Cleveland Clinic Foundation, Cleveland

60637

University of Chicago Comprehensive Cancer Center, Chicago

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

91010

City of Hope Medical Center, Duarte

92093

UC San Diego Moores Cancer Center, La Jolla

92618

City of Hope at Irvine Lennar, Irvine

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER